Sign in with Google. Opens in new tab
ENTITY
Daiichi Sankyo

Daiichi Sankyo (4568 JP)

185
Analysis
Health CareJapan
Daiichi Sankyo Co, Ltd is a holding company established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals.
more
bullishDaiichi Sankyo
27 Jun 2025 00:30

Daiichi Sankyo (4568 JP): FDA Goes Datroway, Daiichi in Contention for the Next “Enhertu” Moment

Daiichi Sankyo received FDA approval for Datroway for certain types of NSCLC. This is the second FDA-approved indication for the drug, which came...

Logo
633 Views
Share
bullishDaiichi Sankyo
26 Apr 2025 00:30

Daiichi Sankyo (4568 JP): Strong FY25 Result; Guidance Initiated for FY26; ¥200B Buyback Announced

​Daiichi Sankyo reports strong FY25 results with double-digit growth in revenue and profit, driven by Enhertu. The company expects further growth...

Logo
386 Views
Share
bullishDaiichi Sankyo
13 Feb 2025 10:12

Daiichi Sankyo Placement - Momentum Is Weak but the Deal Is Small

Mizuho Bank is looking to raise US$151m from selling some of its stake in Daiichi Sankyo. In this note, we will talk about the placement and run...

Logo
424 Views
Share
bullishDaiichi Sankyo
03 Feb 2025 09:38

Daiichi Sankyo (4568 JP): Mixed Q3FY25 Result; FY25 Net Profit Guidance Raised; New CEO Appointed

​Daiichi Sankyo reports mixed Q3FY25 results, with revenue up 8% YoY but net profit down 7%. Enhertu revenue sees strong growth. Company raises...

Logo
391 Views
Share
bullishDaiichi Sankyo
21 Jan 2025 00:30

Daiichi Sankyo (4568 JP): US Approval for Second ADC Drug to Drive Accelerated Growth

​FDA approves Daiichi Sankyo's Datroway for second-line treatment of breast cancer. Supported by AstraZeneca's commercialization expertise, the...

Logo
342 Views
Share
x